-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Royalty Pharma plc quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to 2024.
- Royalty Pharma plc Nonoperating Income (Expense) for the quarter ending December 31, 2024 was -$27.2M, a 126% decline year-over-year.
- Royalty Pharma plc Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $38.4M, a 81.5% decline year-over-year.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2024 was $38.4M, a 81.5% decline from 2023.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2023 was $208M.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2022 was -$77M, a 59.4% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)